Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-BX102 with or without pembrolizumab in advanced solid tumors
NCT05174585Phase 2Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of jieruimab in solid tumor, sponsored by Jacobio Pharmaceuticals. Started Aug 2022; status: completed.
02
Drugs
jieruimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05174585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174585.